The ACOD1 Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human epithelial ovarian cancer cell line. This loss-of-function model disrupts the expression of the aconitate decarboxylase 1 (ACOD1) gene, also known as immune-responsive gene 1 (IRG1), enabling the study of itaconate-mediated signaling in cancer and inflammatory contexts. The polyclonal nature of the knockout pool reflects a heterogeneous mixture of edits across the cell population, providing a robust tool for investigating ACOD1-dependent metabolic and immune regulatory mechanisms without clonal selection artifacts. Researchers can employ this system to dissect the role of ACOD1 in immunometabolism, drug resistance, and tumor microenvironment interactions, with applications spanning oncology, immunology, and infectious disease research.
The parental A2780 cell line is a well-characterized epithelial ovarian carcinoma model originally established from an untreated patient. It retains key pathological features of high-grade serous ovarian cancer, including rapid proliferation, tumorigenic potential, and sensitivity to platinum-based chemotherapeutics. As an adherent cell line with stable growth characteristics, A2780 is frequently used in drug sensitivity screens, migration and invasion assays, and metabolic profiling. The ACOD1 knockout in this background provides a physiologically relevant platform for exploring how itaconate production influences ovarian cancer cell fitness, stress adaptation, and response to anti-inflammatory or anticancer agents.
ACOD1 encodes the mitochondrial enzyme aconitate decarboxylase, which catalyzes the conversion of the TCA cycle intermediate cis-aconitate to itaconate. Itaconate is a pivotal immunometabolite with multifaceted anti-inflammatory and antioxidant functions. Mechanistically, itaconate inhibits succinate dehydrogenase (SDH), leading to succinate accumulation and stabilization of hypoxia-inducible factor 1?? (HIF-1??). It also directly alkylates cysteine residues on KEAP1, enabling Nrf2 liberation and transcriptional activation of detoxifying and antioxidant genes such as HMOX1 and NQO1. Furthermore, itaconate suppresses the NLRP3 inflammasome and modulates post-transcriptional regulation via HuR, thereby dampening pro-inflammatory cytokine production. Expression of ACOD1 is strongly induced by Toll-like receptor ligands (e.g., LPS) and cytokines (TNF??, IFN??) through transcription factors NF-??B, IRF1, and STAT1, placing itaconate synthesis at the nexus of immune signaling and metabolic reprogramming.
In the context of ovarian cancer, ACOD1-driven itaconate production may contribute to an immunosuppressive tumor microenvironment and alter metabolic vulnerabilities. By inhibiting SDH and activating Nrf2, itaconate can protect cancer cells from oxidative stress and chemotherapeutic damage, potentially facilitating drug resistance. Disruption of ACOD1 in A2780 cells permits the systematic evaluation of itaconate??s role in tumor cell proliferation, apoptosis, migration, and inflammatory signaling. This model is particularly valuable for dissecting the interplay between metabolic adaptation and innate immune pathways within ovarian carcinoma, and for assessing whether targeting ACOD1 could sensitize tumors to existing therapies.
This polyclonal knockout cell population supports a wide array of experimental workflows. Researchers can quantify ACOD1 disruption via Western blotting and RT-qPCR, while functional validation may involve itaconate measurement by LC-MS and SDH enzymatic activity assays. Downstream pathway analysis is facilitated by qPCR for Nrf2 target genes (e.g., HMOX1, NQO1) and assessment of NLRP3 inflammasome activation. The model is well-suited for investigating drug sensitivity using cell viability assays, evaluating migratory behavior in transwell systems, and performing global transcriptomic (RNA-seq) or metabolic flux analyses. Applications extend to studies of immune evasion, inflammatory bowel disease, sepsis, and rheumatoid arthritis. For further details or technical support, please contact Ascent Research.
